As the first HER-2 dimerization inhibitor, pertuzumab (a monoclonal antibody), also exhibits antitumor activity on human colon cancer cells in vitro and in vivo, in particular when combined with erlotinib (36). This evidence concerns the gene ERBB2 and malignant colon neoplasm.